A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/05/2002	US6475797 Antisense modulation of SR-CYP expression
11/05/2002	US6475796 Vascular endothelial growth factor variants
11/05/2002	US6475795 Use of hyaluronan in gene therapy
11/05/2002	US6475791 Uses for DNA structure-specific recognition protein
11/05/2002	US6475789 Human telomerase catalytic subunit: diagnostic and therapeutic methods
11/05/2002	US6475785 Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C
11/05/2002	US6475781 Trans-dominant suppressor genes for oligomeric proteins
11/05/2002	US6475778 Differentiation enhancing factors and uses therefor
11/05/2002	US6475775 PARG, a GTPase activating protein which interacts with PTPL1
11/05/2002	US6475766 Human osteoclast-derived cathepsin
11/05/2002	US6475763 Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
11/05/2002	US6475755 For therapy and prophylaixs of multiple myeloma, castleman's diseases, mesangial glomerulonephritis, osteoporosis, lymphomas, rheumatoid arthritis, systemic lupus eryhthematosus
11/05/2002	US6475753 94 Human Secreted Proteins
11/05/2002	US6475746 Method of obtaining a composition comprising a 5-HT1D selective compound
11/05/2002	US6475741 Antiinflammatory agents
11/05/2002	US6475735 Human BMP-2 promoter and method for exploring bone-related substance by using the same
11/05/2002	US6475718 Genetically engineered eukaryotic cell; for prevention of viral infections; viricides
11/05/2002	US6475546 Process for producing enzyme-containing granules
11/05/2002	US6475533 Treating ulcerative colitis, reducing side effects of cancer treatments, improving the bowel movement of a patient who has undergone intestinal ablation or has an artificial anus
11/05/2002	US6475524 Composition of matter
11/05/2002	US6475519 Oil-free pharmaceutical compositions containing cyclosporin A
11/05/2002	US6475511 Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
11/05/2002	US6475507 Sustained release compositions and the process for their preparation
11/05/2002	US6475492 Peptides and assays for the diagnosis of lyme disease
11/05/2002	US6475491 Treatment of HIV and other viral infections using combinatorial therapy
11/05/2002	US6475490 Compositions and methods for promoting tissue repair using heat shock proteins
11/05/2002	US6475488 Methods of inhibiting angiogenesis and ameliorating cancer by using superfibronectin
11/05/2002	US6475487 Treatment of a patient by administering an antibody that inhibits cathepsin O
11/05/2002	US6475485 Two novel human cathepsin proteins
11/05/2002	US6475484 Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
11/05/2002	US6475482 Genetically modified tumor-targeted bacteria with reduce virulence
11/05/2002	US6475477 Radio-opaque polymer biomaterials
11/05/2002	US6475468 Modulated release particles for aerosol delivery
11/05/2002	US6475182 Fluidic media introduction apparatus
11/05/2002	CA2324467C Formulations for protection of peg-interferon alpha conjugates
11/05/2002	CA2234396C Method for production of native human leukocyte (alpha) interferon
11/05/2002	CA2147124C Erythropoietin analogs
11/05/2002	CA2138925C Method of producing reconstituted lipoproteins
11/05/2002	CA2109322C Bombesin analogs
11/05/2002	CA2091449C Cloning and sequencing of allergens of dermatophagoides (house dust mite)
11/05/2002	CA2037779C Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
11/05/2002	CA2011833C Novel polypeptide and production thereof
11/05/2002	CA1341396C Cyclosporin crystal form, processes for its production pharmaceutical compositions containing it and its use
11/02/2002	CA2346154A1 Gastrin receptor-avid peptide conjugates
10/2002
10/31/2002	WO2002086170A1 Tankyrase h, compositions involved in the cell cycle and methods of use
10/31/2002	WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002	WO2002086141A1 Glycopeptide antibiotics
10/31/2002	WO2002086136A1 Process for the manufacture of a fermented health-promoting product
10/31/2002	WO2002086134A2 Buffer solution for electroporation and a method comprising the use of the same
10/31/2002	WO2002086124A2 Human chemokine-13
10/31/2002	WO2002086123A2 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/31/2002	WO2002086118A1 Compositions and methods to control bleeding
10/31/2002	WO2002086117A1 Compositions and methods to control bleeding
10/31/2002	WO2002086113A2 Enzyme and snp marker for disease
10/31/2002	WO2002086109A1 Method of inhibition of hiv replication by leukemia inhibitory factor
10/31/2002	WO2002086101A2 Core-glycosylated hcv envelope proteins
10/31/2002	WO2002086100A2 Expression of core-glycosylated hcv envelope proteins in yeast
10/31/2002	WO2002086093A2 Methods of using a hyaluronan receptor
10/31/2002	WO2002086091A2 Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
10/31/2002	WO2002086090A2 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002	WO2002086087A2 Cytokine protein family
10/31/2002	WO2002086079A2 T1r3 a novel taste receptor
10/31/2002	WO2002086076A2 Polynucleotides and polypeptides associated with the nf-kb pathway
10/31/2002	WO2002086075A2 Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
10/31/2002	WO2002086071A2 Cancer-testis antigens
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002086063A2 Xenobiotic compound modulated expression systems and uses therefor
10/31/2002	WO2002086061A2 Vesicle-associated proteins
10/31/2002	WO2002086058A2 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence
10/31/2002	WO2002085948A1 Repressors for hiv transcription and methods thereof
10/31/2002	WO2002085947A1 Soluble protein from malaria parasite
10/31/2002	WO2002085943A2 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
10/31/2002	WO2002085941A2 Modified interferon alpha with reduced immunogenicity
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085939A1 Novel molecules of the card-related protein family and uses thereof
10/31/2002	WO2002085938A1 Anti-obesity polypeptides
10/31/2002	WO2002085937A2 Inflammation-specific peptides and the uses thereof
10/31/2002	WO2002085934A2 Antibacterial peptides, compositions containing same and uses thereof
10/31/2002	WO2002085932A2 Constructs and methods for expression of recombinant hcv envelope proteins
10/31/2002	WO2002085931A1 Interleukin-1 homolog zil1a7
10/31/2002	WO2002085930A2 Immunomodulating agents from parasitic worms and method for isolation thereof
10/31/2002	WO2002085929A1 Process for preparing lipid ii
10/31/2002	WO2002085928A2 Modified cyclosporine which can be used as a pro-drug and use thereof
10/31/2002	WO2002085927A1 Novel anti-inflammatory peptides
10/31/2002	WO2002085923A2 In vivo incorporation of unnatural amino acids
10/31/2002	WO2002085847A2 Glycine, n-[n-l-gamma-glutamyl-3-(nitrosothio)-l-valyl] and use thereof
10/31/2002	WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002	WO2002085447A2 Microprojection array having a beneficial agent containing coating
10/31/2002	WO2002085422A1 Drug delivery matrices to enhance wound healing
10/31/2002	WO2002085416A1 Viral vectors having reduced virulence
10/31/2002	WO2002085413A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
10/31/2002	WO2002085409A2 Methods and compositions for inducing an immune response to an antigen
10/31/2002	WO2002085408A1 Method of production of insulin-containing oil-based preparation for oral
10/31/2002	WO2002085407A1 Method of optimizing growth hormone replacement
10/31/2002	WO2002085406A1 Methods and compositions for treating conditions associated with insulin resistance
10/31/2002	WO2002085405A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
10/31/2002	WO2002085404A1 Lkb1-binding proteins
10/31/2002	WO2002085403A1 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5
10/31/2002	WO2002085402A1 Methods and compositions for treating oral and eosophageal lesions
10/31/2002	WO2002085401A1 Retrocyclins: antiviral and antimicrobial peptides

1 ... 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 ... 3163